CN106061995A - Uspa2蛋白质构建体及其用途 - Google Patents

Uspa2蛋白质构建体及其用途 Download PDF

Info

Publication number
CN106061995A
CN106061995A CN201580010155.6A CN201580010155A CN106061995A CN 106061995 A CN106061995 A CN 106061995A CN 201580010155 A CN201580010155 A CN 201580010155A CN 106061995 A CN106061995 A CN 106061995A
Authority
CN
China
Prior art keywords
seq
protein
uspa2
immunogenic composition
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580010155.6A
Other languages
English (en)
Chinese (zh)
Inventor
N.布莱斯
C.卡斯塔多
P.乔梅茨
M.德沃钦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to CN202010194047.1A priority Critical patent/CN111499701A/zh
Publication of CN106061995A publication Critical patent/CN106061995A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1218—Acinetobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201580010155.6A 2014-02-24 2015-02-20 Uspa2蛋白质构建体及其用途 Pending CN106061995A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010194047.1A CN111499701A (zh) 2014-02-24 2015-02-20 Uspa2蛋白质构建体及其用途

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461943909P 2014-02-24 2014-02-24
US61/943,909 2014-02-24
US201461946932P 2014-03-03 2014-03-03
US201461946937P 2014-03-03 2014-03-03
US61/946,937 2014-03-03
US61/946,932 2014-03-03
PCT/IB2015/051308 WO2015125118A1 (en) 2014-02-24 2015-02-20 Uspa2 protein constructs and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010194047.1A Division CN111499701A (zh) 2014-02-24 2015-02-20 Uspa2蛋白质构建体及其用途

Publications (1)

Publication Number Publication Date
CN106061995A true CN106061995A (zh) 2016-10-26

Family

ID=52629643

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580010155.6A Pending CN106061995A (zh) 2014-02-24 2015-02-20 Uspa2蛋白质构建体及其用途
CN202010194047.1A Pending CN111499701A (zh) 2014-02-24 2015-02-20 Uspa2蛋白质构建体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010194047.1A Pending CN111499701A (zh) 2014-02-24 2015-02-20 Uspa2蛋白质构建体及其用途

Country Status (28)

Country Link
US (3) US10040832B2 (https=)
EP (2) EP3110438B1 (https=)
JP (1) JP6585085B2 (https=)
KR (1) KR102515835B1 (https=)
CN (2) CN106061995A (https=)
AU (1) AU2015220369B2 (https=)
BE (1) BE1022345A9 (https=)
BR (1) BR112016019525B1 (https=)
CA (1) CA2939862C (https=)
CY (2) CY1121535T1 (https=)
DK (2) DK3110438T3 (https=)
EA (1) EA034352B1 (https=)
ES (2) ES2715674T3 (https=)
HR (2) HRP20211926T1 (https=)
HU (2) HUE057505T2 (https=)
IL (1) IL246994B (https=)
LT (2) LT3110438T (https=)
ME (1) ME03335B (https=)
MX (1) MX376079B (https=)
PL (2) PL3110438T3 (https=)
PT (2) PT3498292T (https=)
RS (2) RS58451B1 (https=)
SG (1) SG11201606272PA (https=)
SI (2) SI3110438T1 (https=)
SM (2) SMT202100728T1 (https=)
TW (1) TW201620927A (https=)
UY (1) UY36006A (https=)
WO (1) WO2015125118A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110662557A (zh) * 2017-03-31 2020-01-07 葛兰素史克知识产权开发有限公司 免疫原性组合物、用途和治疗方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
CA3063954A1 (en) 2017-05-30 2018-12-06 Glaxosmithline Biologicals S.A. Methods for manufacturing an adjuvant
JP2020530478A (ja) * 2017-08-14 2020-10-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫応答を強化する方法
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
GB201803692D0 (en) * 2018-03-08 2018-04-25 Glaxosmithkline Biologicals Sa Immunogenic composition
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
WO2020039033A1 (en) * 2018-08-23 2020-02-27 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
JP7640473B2 (ja) 2019-06-05 2025-03-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
AU2020325569B2 (en) * 2019-08-05 2024-01-18 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein D polypeptide
CA3148924A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Immunogenic composition
US20230266317A1 (en) 2019-09-11 2023-08-24 Glaxosmithkline Biologicals Sa Antigen binding protein and assays
JP2024510717A (ja) 2021-02-22 2024-03-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物、使用及び方法
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101243104A (zh) * 2005-08-10 2008-08-13 阿恩·福斯格伦股份公司 卡他莫拉氏菌与上皮细胞、细胞外基质蛋白及补体系统的相互作用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
ATE157882T1 (de) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
KR100615109B1 (ko) 1996-12-20 2006-08-22 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모렉셀라 카타르할리스의 ｕｓｐａ1, ｕｓｐａ2 항원
AU9475001A (en) 2000-09-26 2002-04-08 Hybridon Inc Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
WO2002083710A2 (en) * 2001-04-13 2002-10-24 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
BR0211494A (pt) * 2001-07-27 2004-08-17 Chiron Srl Adesinas de meningococo nada, app e orf 40
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
WO2007018463A2 (en) * 2005-08-10 2007-02-15 Arne Forsgren Ab Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
AU2007206114B2 (en) * 2006-01-17 2013-01-24 Arne Forsgren A novel surface exposed Haemophilus influenzae protein (protein E; pE)
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
JP2014516028A (ja) * 2011-05-11 2014-07-07 リースベック ヘルスケア スウェーデン アクティエボラーグ ラミニン及びビトロネクチン結合特性を有するタンパク質ｆ−新規インフルエンザ菌付着因子
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101243104A (zh) * 2005-08-10 2008-08-13 阿恩·福斯格伦股份公司 卡他莫拉氏菌与上皮细胞、细胞外基质蛋白及补体系统的相互作用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOHAN SVENSSON等: "Histidine tag fusion increases expression levels of active recombinant amelogenin in Escherichia coli", 《PROTEIN EXPRESSION AND PURIFICATION》 *
程晨等: "His-tag对胆固醇氧化酶基因在大肠杆菌中表达的影响", 《工业微生物》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110662557A (zh) * 2017-03-31 2020-01-07 葛兰素史克知识产权开发有限公司 免疫原性组合物、用途和治疗方法

Also Published As

Publication number Publication date
PT3498292T (pt) 2021-11-18
JP2017507181A (ja) 2017-03-16
SMT202100728T1 (it) 2022-01-10
EP3110438B1 (en) 2019-01-02
LT3498292T (lt) 2021-11-25
TW201620927A (zh) 2016-06-16
IL246994A0 (en) 2016-09-29
EA201691611A1 (ru) 2016-12-30
ME03335B (me) 2019-10-20
SI3498292T1 (sl) 2022-01-31
CA2939862A1 (en) 2015-08-27
MX2016010954A (es) 2016-11-11
US10745449B2 (en) 2020-08-18
CY1124979T1 (el) 2022-11-25
HUE042054T2 (hu) 2019-06-28
EP3498292A1 (en) 2019-06-19
CY1121535T1 (el) 2020-05-29
DK3498292T3 (da) 2022-01-03
KR20160124774A (ko) 2016-10-28
US10947280B2 (en) 2021-03-16
HUE057505T2 (hu) 2022-05-28
BR112016019525A2 (pt) 2017-10-24
RS58451B1 (sr) 2019-04-30
SMT201900166T1 (it) 2019-05-10
CN111499701A (zh) 2020-08-07
EA034352B1 (ru) 2020-01-30
JP6585085B2 (ja) 2019-10-02
BE1022345A9 (fr) 2016-11-16
PL3498292T3 (pl) 2022-02-14
US20200325184A1 (en) 2020-10-15
BE1022345B1 (fr) 2016-03-25
KR102515835B1 (ko) 2023-03-31
US10040832B2 (en) 2018-08-07
ES2899300T3 (es) 2022-03-10
SI3110438T1 (sl) 2019-05-31
BR112016019525B1 (pt) 2024-01-02
LT3110438T (lt) 2019-04-10
PT3110438T (pt) 2019-03-29
CA2939862C (en) 2022-12-06
DK3110438T3 (en) 2019-03-25
US20180354996A1 (en) 2018-12-13
PL3110438T3 (pl) 2019-06-28
EP3498292B1 (en) 2021-10-20
IL246994B (en) 2020-11-30
AU2015220369B2 (en) 2018-02-01
HRP20211926T1 (hr) 2022-03-18
AU2015220369A1 (en) 2016-09-15
EP3110438A1 (en) 2017-01-04
HRP20190412T1 (hr) 2019-04-19
WO2015125118A1 (en) 2015-08-27
ES2715674T3 (es) 2019-06-05
US20170008932A1 (en) 2017-01-12
RS62592B1 (sr) 2021-12-31
SG11201606272PA (en) 2016-09-29
UY36006A (es) 2015-09-30
MX376079B (es) 2025-03-07

Similar Documents

Publication Publication Date Title
US10947280B2 (en) UspA2 protein constructs and uses thereof
KR20230008801A (ko) Sars-cov-2 항원을 암호화하는 최적화된 뉴클레오티드 서열
CN101969990B (zh) 增强针对艾美球虫属的免疫反应的组合物和方法
CN102037135A (zh) 增强对有鞭毛的细菌的免疫反应的组合物和方法
JP2023098935A (ja) 歯周炎ワクチンおよび関連組成物ならびに使用方法
JP5097544B2 (ja) 炭疽菌からの防御抗原の調製
WO2022034221A1 (en) Salmonella vaccine for the treatment of coronavirus
EP1724342B1 (en) Process for preparing variant of erysipelothrix rhusiopathiae surface protective antigen in e. coli
KR20210146392A (ko) 침습 플라스미드 항원 b의 최적화된 무세포 합성 및 관련 조성물 및 사용 방법
US20230414738A1 (en) Haemophilus influenzae vaccine and methods of use
CN103702684A (zh) 组合疫苗
CN101063116A (zh) 肺炎链球菌自溶酶蛋白及其原核表达纯化工艺和疫苗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20161026

RJ01 Rejection of invention patent application after publication